ArticleFrontiers in endocrinology2026
Combined cord blood metabolomic and clinical signatures discriminate small for gestational age neonates in preeclampsia.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preeclampsia (PE) subjects the fetus to a hostile intrauterine environment and elevates the risk of small for gestational age (SGA). The link between cord blood metabolic signs and PE exposure is still unclear. This connection may affect fetal growth. Methods: We did untargeted metabolomics profiling of cord blood. This involved 37 pregnancies with preeclampsia (PE) and 48 control pregnancies. We used liquid chromatography-mass spectrometry for the analysis. Researchers examined metabolites that showed differential expression. They also analyzed pathway enrichment. We used Spearman's correlation to assess associations between metabolites and clinical indicators, including birth weight. We created a discriminative model for SGA. It combines metabolic features and clinical variables. Results: In the PE group, 205 metabolites changed significantly. Of these, 82 were upregulated and 123 were downregulated. Caffeine metabolism, lysine biosynthesis, and sulfur metabolism were the top three pathways affected. Among the dysregulated metabolites, 2-oxoadipic acid is important in lysine breakdown. It showed a strong negative link with birth weight ( Conclusions: PE greatly changes the cord blood metabolome. This has a primary impact on caffeine, lysine, and sulfur metabolism. 2-Oxoadipic acid is linked to fetal growth restriction. Combining cord blood metabolic signatures with clinical data makes a strong model. These findings reveal metabolite-level disturbances that may help elucidate the metabolic basis of impaired fetal growth in preeclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.